{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:24Z","timestamp":1791665964383,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC011989"],"award-info":[{"award-number":["ZIA BC011989"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADC Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy, identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with limited normal tissue expression and high expression in multiple refractory adult metastatic cancers including small cell lung cancer (SCLC) and adrenocortical carcinoma (ACC), a rare cancer with few effective therapies. In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows in vitro and in vivo activity but is overall limited due to high expression and activity of the drug efflux protein ABCB1 (MDR1, P-glycoprotein). In contrast, ADCT-701 induces complete responses in DLK1\n                    <jats:sup>+<\/jats:sup>\n                    ACC and SCLC in vivo models with low or no ABCB1 expression. Genetic deletion of DLK1 in ACC dramatically downregulates ABCB1 and increases ADC payload and chemotherapy sensitivity through NOTCH1-mediated transdifferentiation. This work identifies DLK1 as an immunotherapeutic target that regulates tumor cell plasticity and chemoresistance in ACC and supports an active phase I clinical trial targeting DLK1 with an ADC in ACC and neuroendocrine neoplasms (NCT06041516).\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-60649-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:02:05Z","timestamp":1751353325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-4104","authenticated-orcid":false,"given":"Nai-Yun","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulfo","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-2055","authenticated-orcid":false,"given":"Rosa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2584-3026","authenticated-orcid":false,"given":"Reona","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9109-4409","authenticated-orcid":false,"given":"Karlyne","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-7175","authenticated-orcid":false,"given":"Brigitte","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3108-0758","authenticated-orcid":false,"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Elloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Dhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Taniyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etan","family":"Aber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina F.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosandra N.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-582X","authenticated-orcid":false,"given":"Katja","family":"Kiseljak-Vassiliades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Wierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-4401","authenticated-orcid":false,"given":"Jennifer","family":"Pogoriler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Diskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-7929","authenticated-orcid":false,"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0857-3650","authenticated-orcid":false,"given":"Robert W.","family":"Robey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60649_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"60649_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1634\/theoncologist.12-5-535","volume":"12","author":"M Kunnimalaiyaan","year":"2007","unstructured":"Kunnimalaiyaan, M. & Chen, H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors.  Oncologist 12, 535\u2013542 (2007).","journal-title":"Oncologist"},{"key":"60649_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou, B. et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct. Target. Ther. 7, 95 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"60649_CR4","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7, 302ra136 (2015).","journal-title":"Sci. Transl. Med."},{"key":"60649_CR5","doi-asserted-by":"publisher","unstructured":"Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aav0891 (2019).","DOI":"10.1126\/scitranslmed.aav0891"},{"key":"60649_CR6","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 41, 2893\u20132903 (2023).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"60649_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell Lung cancer.  N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"60649_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GT Consortium","year":"2013","unstructured":"Consortium, G. T. The genotype-tissue expression (GTEx) project. Nat. Genet. 45, 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"key":"60649_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-22-0966","volume":"13","author":"Y Pradat","year":"2023","unstructured":"Pradat, Y. et al. Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. Cancer Discov. 13, 1116\u20131143 (2023).","journal-title":"Cancer Discov."},{"key":"60649_CR10","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ccell.2024.10.003","volume":"42","author":"AK Hamilton","year":"2024","unstructured":"Hamilton, A. K. et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer cell 42, 1970\u20131982 e1977 (2024).","journal-title":"Cancer cell"},{"key":"60649_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"K Chang","year":"2013","unstructured":"Chang, K. et al. The cancer genome atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"60649_CR12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht, M. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 31, 1476\u20131490 (2020).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"60649_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1530\/EJE-13-0519","volume":"169","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez, M. et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur. J. Endocrinol. 169, 891\u2013899 (2013).","journal-title":"Eur. J. Endocrinol."},{"key":"60649_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","volume":"23","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht, M. & Allolio, B. Clinical management of adrenocortical carcinoma. Best. Pract. Res. Clin. Endocrinol. Metab. 23, 273\u2013289 (2009).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"60649_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng, S. et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer cell 29, 723\u2013736 (2016).","journal-title":"Cancer cell"},{"key":"60649_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","volume":"15","author":"TJ Giordano","year":"2009","unstructured":"Giordano, T. J. et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 15, 668\u2013676 (2009).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"60649_CR17","doi-asserted-by":"crossref","unstructured":"Mariniello, K. et al. Dlk1 is a novel adrenocortical stem\/progenitor cell marker that predicts malignancy in adrenocortical carcinoma. Cancer Commun. 10.1002\/cac2.70012 (2025).","DOI":"10.1101\/2024.08.22.609117"},{"key":"60649_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1158\/1538-7445.AM2018-744","volume":"78","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi, F. et al. Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors. Cancer Res. 78, 744\u2013744 (2018).","journal-title":"Cancer Res."},{"key":"60649_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","volume":"26","author":"R van Geel","year":"2015","unstructured":"van Geel, R. et al. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-Glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates. Bioconjug. Chem. 26, 2233\u20132242 (2015).","journal-title":"Bioconjug. Chem."},{"key":"60649_CR20","doi-asserted-by":"publisher","unstructured":"J. M. M. Verkade et al. A polar sulfamide spacer significantly enhances the manufacturability, stability, and therapeutic index of antibody-drug conjugates. Antibodies 7, https:\/\/doi.org\/10.3390\/antib7010012 (2018).","DOI":"10.3390\/antib7010012"},{"key":"60649_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/13543784.2011.573477","volume":"20","author":"JA Hartley","year":"2011","unstructured":"Hartley, J. A. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 20, 733\u2013744 (2011).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"60649_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mce.2011.08.041","volume":"351","author":"T Wang","year":"2012","unstructured":"Wang, T. & Rainey, W. E. Human adrenocortical carcinoma cell lines. Mol. Cell Endocrinol. 351, 58\u201365 (2012).","journal-title":"Mol. Cell Endocrinol."},{"key":"60649_CR23","doi-asserted-by":"publisher","unstructured":"A. J. H. Sedlack et al. Preclinical Models of Adrenocortical Cancer. Cancers 15, https:\/\/doi.org\/10.3390\/cancers15112873 (2023).","DOI":"10.3390\/cancers15112873"},{"key":"60649_CR24","doi-asserted-by":"publisher","first-page":"e65624","DOI":"10.1371\/journal.pone.0065624","volume":"8","author":"HK Ghayee","year":"2013","unstructured":"Ghayee, H. K. et al. Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor. PloS ONE 8, e65624 (2013).","journal-title":"PloS ONE"},{"key":"60649_CR25","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn, M. J. et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) dimer\u2013containing antibody\u2013drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol. Cancer Ther. 15, 2709\u20132721 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"60649_CR26","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","volume":"19","author":"S Corbett","year":"2020","unstructured":"Corbett, S. et al. The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates. Mol. Cancer Ther. 19, 1856\u20131865 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"60649_CR27","doi-asserted-by":"publisher","first-page":"R271","DOI":"10.1530\/ERC-21-0208","volume":"28","author":"JFH Pittaway","year":"2021","unstructured":"Pittaway, J. F. H., Lipsos, C., Mariniello, K. & Guasti, L. The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer. Endocr. Relat. Cancer 28, R271\u2013R287 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"60649_CR28","doi-asserted-by":"publisher","first-page":"L500","DOI":"10.1152\/ajplung.00052.2006","volume":"292","author":"L Shan","year":"2007","unstructured":"Shan, L., Aster, J. C., Sklar, J. & Sunday, M. E. Notch-1 regulates pulmonary neuroendocrine cell differentiation in cell lines and in transgenic mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L500\u2013L509 (2007).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"60649_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"60649_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360\u2013364 (2017).","journal-title":"Nature"},{"key":"60649_CR31","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1093\/nar\/gkac344","volume":"50","author":"S Kojima","year":"2022","unstructured":"Kojima, S. et al. Epigenome editing reveals core DNA methylation for imprinting control in the Dlk1-Dio3 imprinted domain. Nucleic Acids Res. 50, 5080\u20135094 (2022).","journal-title":"Nucleic Acids Res."},{"key":"60649_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jmb.2006.10.043","volume":"367","author":"ML Nueda","year":"2007","unstructured":"Nueda, M. L., Baladron, V., Sanchez-Solana, B., Ballesteros, M. A. & Laborda, J. The EGF-like protein dlk1 inhibits notch signaling and potentiates adipogenesis of mesenchymal cells. J. Mol. Biol. 367, 1281\u20131293 (2007).","journal-title":"J. Mol. Biol."},{"key":"60649_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.clml.2014.06.019","volume":"14","author":"L Benetatos","year":"2014","unstructured":"Benetatos, L. & Hatzimichael, E. Delta-like homologue 1 and its role in the bone marrow niche and hematologic malignancies. Clin. Lymphoma Myeloma Leuk. 14, 451\u2013455 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"60649_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12015-011-9298-7","volume":"8","author":"B Surmacz","year":"2012","unstructured":"Surmacz, B. et al. DLK1 promotes neurogenesis of human and mouse pluripotent stem cell-derived neural progenitors via modulating Notch and BMP signalling. Stem Cell Rev. Rep. 8, 459\u2013471 (2012).","journal-title":"Stem Cell Rev. Rep."},{"key":"60649_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/cvr\/cvr296","volume":"93","author":"P Rodriguez","year":"2012","unstructured":"Rodriguez, P. et al. The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis. Cardiovasc. Res. 93, 232\u2013241 (2012).","journal-title":"Cardiovasc. Res."},{"key":"60649_CR36","doi-asserted-by":"publisher","first-page":"e15055","DOI":"10.1371\/journal.pone.0015055","volume":"5","author":"JN Waddell","year":"2010","unstructured":"Waddell, J. N. et al. Dlk1 is necessary for proper skeletal muscle development and regeneration. PloS ONE 5, e15055 (2010).","journal-title":"PloS ONE"},{"key":"60649_CR37","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1210\/en.2013-1211","volume":"154","author":"L Guasti","year":"2013","unstructured":"Guasti, L. et al. Dlk1 up-regulates Gli1 expression in male rat adrenal capsule cells through the activation of beta1 integrin and ERK1\/2. Endocrinology 154, 4675\u20134684 (2013).","journal-title":"Endocrinology"},{"key":"60649_CR38","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/s41388-018-0658-5","volume":"38","author":"CC Huang","year":"2019","unstructured":"Huang, C. C. et al. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling. Oncogene 38, 3201\u20133215 (2019).","journal-title":"Oncogene"},{"key":"60649_CR39","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3892\/ol.2017.6019","volume":"13","author":"Z Zhong","year":"2017","unstructured":"Zhong, Z., Ye, Y., Guo, W., He, Y. & Hu, W. Relationship between DLK1 gene promoter region DNA methylation and non-small cell lung cancer biological behavior. Oncol. Lett. 13, 4123\u20134126 (2017).","journal-title":"Oncol. Lett."},{"key":"60649_CR40","doi-asserted-by":"publisher","first-page":"112272","DOI":"10.1016\/j.mce.2024.112272","volume":"590","author":"DS Tourigny","year":"2024","unstructured":"Tourigny, D. S. et al. Cellular landscape of adrenocortical carcinoma at single-nuclei resolution. Mol. Cell Endocrinol. 590, 112272 (2024).","journal-title":"Mol. Cell Endocrinol."},{"key":"60649_CR41","doi-asserted-by":"crossref","unstructured":"Popova, L. V. et al. Single nuclei sequencing reveals intratumoral cellular heterogeneity and replication stress in adrenocortical carcinoma. Preprint at 10.1101\/2024.09.30.615695 (2024).","DOI":"10.1101\/2024.09.30.615695"},{"key":"60649_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc3035","volume":"11","author":"P Ranganathan","year":"2011","unstructured":"Ranganathan, P., Weaver, K. L. & Capobianco, A. J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 11, 338\u2013351 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"60649_CR43","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma.  N. Engl. J. Med. 366, 2189\u20132197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"60649_CR44","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1016\/S0021-9258(18)53544-4","volume":"268","author":"J Laborda","year":"1993","unstructured":"Laborda, J., Sausville, E. A., Hoffman, T. & Notario, V. dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line.  J. Biol. Chem. 268, 3817\u20133820 (1993).","journal-title":"J. Biol. Chem."},{"key":"60649_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.seminoncol.2012.11.009","volume":"40","author":"JR Strosberg","year":"2013","unstructured":"Strosberg, J. R. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 40, 120\u2013133 (2013).","journal-title":"Semin Oncol."},{"key":"60649_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","volume":"7","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl. Lung Cancer Res. 7, 32\u201349 (2018).","journal-title":"Transl. Lung Cancer Res."},{"key":"60649_CR47","first-page":"424","volume":"72","author":"P Komminoth","year":"1995","unstructured":"Komminoth, P., Roth, J., Schr\u00f6der, S., Saremaslani, P. & Heitz, P. U. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab. Invest.72, 424\u2013431 (1995).","journal-title":"Lab. Invest."},{"key":"60649_CR48","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/jco.2008.26.15_suppl.2543","volume":"26","author":"ME Menefee","year":"2008","unstructured":"Menefee, M. E. et al. Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). J. Clin. Oncol. 26, 2543\u20132543 (2008).","journal-title":"J. Clin. Oncol."},{"key":"60649_CR49","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","volume":"21","author":"SF Yu","year":"2015","unstructured":"Yu, S. F. et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to Auristatin-based ADCs. Clin. Cancer Res.21, 3298\u20133306 (2015).","journal-title":"Clin. Cancer Res."},{"key":"60649_CR50","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1111\/liv.15411","volume":"42","author":"Y Zhai","year":"2022","unstructured":"Zhai, Y. et al. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma. Liver Int. 42, 2524\u20132537 (2022).","journal-title":"Liver Int."},{"key":"60649_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"60649_CR52","doi-asserted-by":"publisher","first-page":"105422","DOI":"10.1016\/j.jsbmb.2019.105422","volume":"193","author":"I Hadjidemetriou","year":"2019","unstructured":"Hadjidemetriou, I. et al. DLK1\/PREF1 marks a novel cell population in the human adrenal cortex. J. Steroid Biochem. Mol. Biol. 193, 105422 (2019).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"60649_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1369\/00221554211048951","volume":"70","author":"ES Grassi","year":"2022","unstructured":"Grassi, E. S. & Pietras, A. Emerging roles of DLK1 in the stem cell niche and cancer stemness. J. Histochem Cytochem 70, 17\u201328 (2022).","journal-title":"J. Histochem Cytochem"},{"key":"60649_CR54","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1538-7445.AM2024-1896","volume":"84","author":"MS McDermott","year":"2024","unstructured":"McDermott, M. S. et al. Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1). Cancer Res. 84, 1896\u20131896 (2024).","journal-title":"Cancer Res."},{"key":"60649_CR55","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2011.11.032","volume":"318","author":"A Begum","year":"2012","unstructured":"Begum, A., Kim, Y., Lin, Q. & Yun, Z. DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo. Cancer Lett. 318, 26\u201333 (2012).","journal-title":"Cancer Lett."},{"key":"60649_CR56","doi-asserted-by":"publisher","first-page":"9271","DOI":"10.1158\/0008-5472.CAN-09-1605","volume":"69","author":"Y Kim","year":"2009","unstructured":"Kim, Y., Lin, Q., Zelterman, D. & Yun, Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res. 69, 9271\u20139280 (2009).","journal-title":"Cancer Res."},{"key":"60649_CR57","doi-asserted-by":"publisher","first-page":"71466","DOI":"10.18632\/oncotarget.12214","volume":"7","author":"CM Cai","year":"2016","unstructured":"Cai, C. M., Xiao, X., Wu, B. H., Wei, B. F. & Han, Z. G. Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation. Oncotarget 7, 71466\u201371476 (2016).","journal-title":"Oncotarget"},{"key":"60649_CR58","doi-asserted-by":"publisher","first-page":"eadd0422","DOI":"10.1126\/sciadv.add0422","volume":"8","author":"JJ Wilmouth Jr.","year":"2022","unstructured":"Wilmouth, J. J. Jr. et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development. Sci. Adv. 8, eadd0422 (2022).","journal-title":"Sci. Adv."},{"key":"60649_CR59","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s43587-023-00420-2","volume":"3","author":"KM Warde","year":"2023","unstructured":"Warde, K. M. et al. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nat. Aging 3, 846\u2013865 (2023).","journal-title":"Nat. Aging"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60649-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60649-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60649-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:04:59Z","timestamp":1751353499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60649-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60649"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60649-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.09.617077","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nitin Roper and Jaydira Del Rivero have received research funding from ADC Therapeutics for this study. The other authors have no competing interests to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5511"}}